FCM's AI ecosystem - rebuilt from the ground up, connected end-to-end, and unlike anything else in managed travel - goes live for customers across nearly 100 countries in June.
BRISBANE, Australia, May 12, 2026 /PRNewswire/ -- FCM Travel has announced that Sam - already known to customers as the company's AI travel companion - has been fundamentally reimagined. What goes live across more than 90 countries in June is not just an upgrade.
It is a new category. A proprietary AI ecosystem built at the core of FCM's technology, making Sam the intelligence layer running through everything FCM does - not a feature sitting on top of it. For existing customers, what's coming will feel like a different product entirely.
"This is a genuine, game-changing first for the managed travel industry," said John Morhous, Global Chief Experience Officer, FCM Travel. "A lot of our competitors are trying to bolt AI onto existing stacks, but the real power in AI is that the more connected it is, the more you can do with it. Sam is built, not bought - and that compounds over time."
Sam intelligence works across all roles - travellers, arrangers, and travel managers - with equal depth. Most AI in managed travel still focuses on a single point in the journey. Underpinning it all is FCM's proprietary technology architecture, which defines which trusted data sources Sam queries for each interaction, preventing hallucination and ensuring enterprise-grade accuracy.
Customer data is stored in FCM's private environment and never used to train public AI models.
Central to Sam's architecture is its proprietary guardrail system - a capability that goes far beyond hallucination prevention. Travel managers can configure precisely how Sam responds to specific query types, ensuring answers always reflect their policies and rules of engagement.
A traveller not entitled to business class will never receive a recommendation for a premium fare. An out-of-policy hotel will not be surfaced as an option.
Spend thresholds, approval workflows, and supplier preferences are all automatically enforced in conversation, giving organisations the benefits of conversational AI while retaining the programme controls that enterprise travel demands.
"Travellers are tired of fragmented experiences – piecing together more than five tools just to get through a trip," said Morhous.
"Sam isn't a single point of support. It's there throughout the entire journey, for every person in a travel programme. Because our AI is proprietary, the accuracy and compliance enterprises need isn't bolted on - it's built in."
"But what truly sets this apart is our people. Sam works alongside our travel consultants so that when a human moment matters most - a disruption, a complex itinerary, an urgent need - our experts step in with the speed, context, and care that no technology alone can replicate. Sam makes those moments more meaningful, not less."
At launch, Sam delivers end-to-end trip support across the full traveller journey, with real-time programme data intelligence for travel managers through plain-language conversation, seamless handoff to FCM consultants with full context intact, and a unique smart redirect into customers' existing booking tools - the only AI solution in managed travel to offer this.
"June is only the beginning," said Morhous. "Because we own our technology end-to-end, every release makes our customers' programmes smarter.
"Sam intelligence compounds - and so does the advantage it creates for the organisations that run on it. What's coming next will redefine what clients expect from a travel management company."
Video - https://mma.prnewswire.com/media/2977327/video.mp4
Photo - https://mma.prnewswire.com/media/2977328/image.jpg
Logo - https://mma.prnewswire.com/media/2977329/FCM_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-activation-of-sam-ushers-in-a-new-era-of-ai-intelligence-for-fcm-travel-customers-302769089.html
Sandoz hat im ersten Quartal 2026 trotz erheblicher Verwerfungen im Penicillin-Geschäft weiteres Wachstum erzielt. Der Umsatz des Schweizer Generika- und Biosimilar-Spezialisten belief sich zwischen Januar und März auf 2,76 Milliarden US-Dollar, ein Plus von 11 Prozent gegenüber dem Vorjahreszeitraum. Zu konstanten Wechselkursen legten die Erlöse um 3 Prozent zu. Der Konzern bestätigt nach eigenen Angaben seinen Ausblick für das Gesamtjahr.
Treiber der Entwicklung war vor allem das höhermargige Biosimilar-Geschäft, das die frühere Novartis-Tochter weiter ausgebaut hat. Dagegen stand die grössere Generika-Sparte erneut unter Druck, weil sich die Marktverwerfungen im Penicillin-Segment fortsetzten. Klammerte man die negativen Auswirkungen aus dem Antibiotika-Geschäft aus, hätte das Umsatzplus zu konstanten Wechselkursen bei rund 5 Prozent gelegen und damit im Rahmen der Unternehmensprognose.
Die Belastungen resultieren aus einem anhaltenden Preisverfall bei wichtigen Penicillin-Wirkstoffen (Active Pharmaceutical Ingredients), der bereits im Vorjahr eingesetzt hatte. Hintergrund sind US-Zölle, die chinesische Anbieter dazu veranlasst haben, ihre Penicillin-Mengen verstärkt nach Europa umzuleiten. Das zusätzliche Angebot hat dort die Preise deutlich gedrückt. Parallel dazu führten in Indien eingeführte Mindestpreisvorschriften dazu, dass weniger chinesische Ware in diesen Markt floss, was den Wettbewerbsdruck in Europa zusätzlich verschärfte und den Preisdruck weiter verstärkte.
Laut Sandoz konzentrieren sich die heftigsten Auswirkungen dieser Entwicklung auf das erste Quartal, die verbleibenden Effekte sollen sich nun schrittweise abschwächen. Analysten verweisen darauf, dass das Unternehmen ohne den Antibiotika-Gegenwind im Rahmen seiner Guidance gewachsen wäre. Der Konzern bleibt damit auf Wachstumskurs, muss sich im Generika-Kerngeschäft jedoch weiterhin in einem von handelspolitischen Eingriffen und regulatorischen Änderungen verzerrten Marktumfeld behaupten.
